Literature DB >> 31142241

Persistent critical illness: baseline characteristics, intensive care course, and cause of death.

Jai N Darvall1, Tristan Boonstra2, Jen Norman2, Donal Murphy2, Michael Bailey3, Theodore J Iwashyna4, Sean M Bagshaw5, Rinaldo Bellomo2.   

Abstract

OBJECTIVES: Persistent critical illness (PerCI) is associated with high mortality and discharge to institutional care. Little is known about factors involved in its progression, complications and cause of death. We aimed to identify such factors and the time when the original illness was no longer the reason for intensive care unit (ICU) stay.
DESIGN: Retrospective matched case-control study using an accepted PerCI definition (> 10 days in ICU).
SETTING: Single-centre tertiary metropolitan ICU. PARTICIPANTS: All adult patients admitted during a 2-year period were eligible, matched on diagnostic code, gender, age and risk of death. MAIN
RESULTS: Seventy-two patients staying > 10 days (PerCI cases) were matched to 72 control patients. The original illness was no longer a cause for continued ICU stay after a median of 10 days (interquartile range [IQR], 7-16) versus 2 days (IQR, 0-3); P < 0.001. Patients with PerCI were more likely to develop new sepsis (52.8% v 23.6%; P < 0.001), delirium (37.5% v 9.7%; P < 0.001), ICU-acquired weakness (15.3% v 0%, P = 0.001), and to be discharged to chronic care or rehabilitation (37.5% v 16.7%; P < 0.005). Death resulting from sepsis with multi-organ failure occurred in 16.7% v 8.3% of control patients (P = 0.13), and one-third of patients with PerCI were not mechanically ventilated on Day 10.
CONCLUSION: PerCI likely results from complications acquired after ICU admission and mostly unrelated to the original illness; by Day 10, the original illness does not appear to be its cause, and new sepsis appears an important association.

Entities:  

Mesh:

Year:  2019        PMID: 31142241

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  7 in total

1.  Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis.

Authors:  Jingjing Huang; Xiaoli Wang; Chenxia Hao; Wanhua Yang; Weixia Zhang; Jialin Liu; Hongping Qu
Journal:  Intern Emerg Med       Date:  2021-03-16       Impact factor: 3.397

2.  The heterogeneity of prolonged ICU hospitalisations.

Authors:  Elizabeth Marie Viglianti; Jacqueline M Kruser; Theodore Iwashyna
Journal:  Thorax       Date:  2019-09-18       Impact factor: 9.139

3.  Hospital-level variation in the development of persistent critical illness.

Authors:  Elizabeth M Viglianti; Sean M Bagshaw; Rinaldo Bellomo; Joanne McPeake; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna
Journal:  Intensive Care Med       Date:  2020-06-04       Impact factor: 17.440

4.  Acquisition of new medical devices among the persistently critically ill: A retrospective cohort study in the Veterans Affairs.

Authors:  Elizabeth M Viglianti; Erin F Carlton; Joanne McPeake; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

5.  Timing of Onset, Burden, and Postdischarge Mortality of Persistent Critical Illness in Scotland, 2005-2014: A Retrospective, Population-Based, Observational Study.

Authors:  Martin Shaw; Elizabeth M Viglianti; Joanne McPeake; Sean M Bagshaw; David Pilcher; Rinaldo Bellomo; Theodore J Iwashyna; Tara Quasim
Journal:  Crit Care Explor       Date:  2020-04-29

6.  Survivorship of Patients After Long Intensive Care Stay With Exploration and Experience in a New Zealand Cohort (SPLIT ENZ): Protocol for a Mixed Methods Study.

Authors:  Lynsey Sutton; Elliot Bell; Susanna Every-Palmer; Mark Weatherall; Paul Skirrow
Journal:  JMIR Res Protoc       Date:  2022-03-17

7.  Impact of frailty on persistent critical illness: a population-based cohort study.

Authors:  Jai N Darvall; Rinaldo Bellomo; Michael Bailey; Paul J Young; Kenneth Rockwood; David Pilcher
Journal:  Intensive Care Med       Date:  2022-02-04       Impact factor: 41.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.